These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1033 related items for PubMed ID: 12087568

  • 21. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK.
    Cancer; 2004 Feb 15; 100(4):859-68. PubMed ID: 14770445
    [Abstract] [Full Text] [Related]

  • 22. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
    Roger SD, Kolmakova E, Fung M, Malecki R, Vinhas J, Dellanna F, Thomas M, Manamley N, Ferenczi S.
    Nephrology (Carlton); 2014 May 15; 19(5):266-74. PubMed ID: 24506498
    [Abstract] [Full Text] [Related]

  • 23. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
    Agarwal A, Silver MR, Walczyk M, Liu W, Audhya P.
    J Am Med Dir Assoc; 2007 Feb 15; 8(2):83-90. PubMed ID: 17289537
    [Abstract] [Full Text] [Related]

  • 24. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.
    Canon JL, Vansteenkiste J, Bodoky G, Mateos MV, Bastit L, Ferreira I, Rossi G, Amado RG.
    J Natl Cancer Inst; 2006 Feb 15; 98(4):273-84. PubMed ID: 16478746
    [Abstract] [Full Text] [Related]

  • 25. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
    Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P, Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group.
    Circulation; 2008 Jan 29; 117(4):526-35. PubMed ID: 18195176
    [Abstract] [Full Text] [Related]

  • 26. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep 29; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr 29; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 28. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul 29; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 29. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group.
    Curr Med Res Opin; 2008 Mar 29; 24(3):625-37. PubMed ID: 18208642
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.
    Agrawal V, Mukherjee S, Kosuri R, Dumler F.
    Am J Ther; 2010 Mar 29; 17(5):469-75. PubMed ID: 19770634
    [Abstract] [Full Text] [Related]

  • 32. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr 29; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 33. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
    Roger SD, Cooper B.
    Nephrology (Carlton); 2004 Aug 29; 9(4):223-8. PubMed ID: 15363054
    [Abstract] [Full Text] [Related]

  • 34. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
    Bajo MA, Pérez Fontán M, Remón C, Sánchez-Tomero JA, Lladós F, Selgas R.
    Nefrologia; 2009 Aug 29; 29(2):136-42. PubMed ID: 19396319
    [Abstract] [Full Text] [Related]

  • 35. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
    Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S.
    Am J Nephrol; 2004 Aug 29; 24(4):453-60. PubMed ID: 15331889
    [Abstract] [Full Text] [Related]

  • 36. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA, Harpe SH, Brophy GM.
    Pharmacotherapy; 2007 Apr 29; 27(4):535-41. PubMed ID: 17381380
    [Abstract] [Full Text] [Related]

  • 37. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
    Lucas C, Carrera F, Jorge C, Boquinhas H, Pais MJ.
    Nephrol Dial Transplant; 2006 Nov 29; 21(11):3202-6. PubMed ID: 16891651
    [Abstract] [Full Text] [Related]

  • 38. Developing an algorithm to convert erythropoietin dosing to darbepoetin alfa.
    Capelli JP, Kushner H.
    Nephrol News Issues; 2006 Mar 29; 20(3):33, 35, 39 passim. PubMed ID: 16532992
    [Abstract] [Full Text] [Related]

  • 39. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A, Epoetin Zeta Study Group.
    Adv Ther; 2010 Feb 29; 27(2):105-17. PubMed ID: 20369312
    [Abstract] [Full Text] [Related]

  • 40. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS, Scott-Douglas NW, Singh AK, Toto R, Uno H, Ivanovich P.
    Am J Kidney Dis; 2013 Feb 29; 61(2):238-46. PubMed ID: 23159232
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.